APYX Earnings Date: Nov 5, 2026 (Estimated) — Apyx Medical Corporation
NASDAQ · Healthcare · Medical Devices
Updated
When is APYX's next earnings date?
Apyx Medical Corporation (APYX) is expected to report Q3 2026 earnings on Thursday, November 5, 2026 at 7:00 AM ET (before market open); the date is an estimate and has not been confirmed by the company. The consensus estimate is EPS of -$0.07 on revenue of $13.3M.
How did APYX do in its last earnings report?
In its most recent report on Aug 6, 2026 (Q2 2026), Apyx Medical Corporation posted EPS of -$0.07 versus the -$0.08 estimate, a beat of 22.2%. Revenue was $13.9M against a $13.2M estimate. The stock's 1-day post-earnings move was -2.6%.
How much does APYX stock move after earnings?
APYX beat EPS estimates in 6 of its last 8 reported quarters. Over the last 8 reports the stock moved an average of 13.9% (up or down) in the day after earnings.
About Apyx Medical Corporation
Apyx Medical Corporation, an energy technology company, designs, develops, manufactures, and sells electrosurgical equipment and medical devices in the United States and internationally. The company operates through two segments: Surgical Aesthetics and Original Equipment Manufacturing (OEM). It offers helium plasma generator for the delivery of RF energy and helium plasma to cut, coagulate, and ablate soft tissue during open and minimally invasive surgical procedures; and a portfolio of single-use handpieces and accessories for open and laparoscopic procedures. The company’s helium plasma technology products are marketed and sold under the Renuvion name in the cosmetic surgery market and under the J-Plasma name in the hospital surgical market. It also develops and manufactures OEM generators and related accessories. The company was formerly known as Bovie Medical Corporation and changed its name to Apyx Medical Corporation in January 2019. Apyx Medical Corporation was incorporated in 1982 and is based in Clearwater, Florida.
Earnings History
| Date | Period | EPS Est. | EPS Act. | Surprise | Revenue | Result | 1D Δ | 1W Δ | 1M Δ |
|---|---|---|---|---|---|---|---|---|---|
| 2026-08-06 | Q2 2026 | -0.08 | -0.07 | +22.22% | $13.9M | ✅ Beat | -2.64% | -26.92% | -26.68% |
| 2026-05-07 | Q1 2026 | -0.11 | -0.05 | +54.55% | $12.5M | ✅ Beat | +21.92% | +31.51% | +53.08% |
| 2026-03-10 | Q4 2025 | -0.06 | -0.03 | +50.00% | $19.2M | ✅ Beat | +0.58% | +7.00% | +11.08% |
| 2025-11-06 | Q3 2025 | -0.10 | -0.05 | +50.00% | $12.9M | ✅ Beat | +6.69% | +37.90% | +25.48% |
| 2025-03-13 | Q4 2024 | -0.16 | -0.12 | +25.00% | $14.2M | ✅ Beat | -2.80% | +1.87% | -17.76% |
| 2024-11-08 | Q3 2024 | -0.19 | -0.14 | +26.32% | $11.5M | ✅ Beat | +24.59% | +5.74% | +34.43% |
| 2024-05-09 | Q1 2024 | -0.21 | -0.22 | -4.76% | $10.2M | ❌ Miss | +22.96% | +4.44% | +18.52% |
| 2024-03-21 | Q4 2023 | -0.18 | -0.28 | -55.56% | $14.7M | ❌ Miss | -28.65% | -23.78% | -28.65% |
Showing last 8 quarters.
Revenue by segment & region
By region
Q2 FY26 · $13.9M total
| Segment | Share | Revenue | YoY | Q4 FY24 | Q1 FY25 | Q2 FY25 | Q3 FY25 |
|---|---|---|---|---|---|---|---|
| UNITED STATES | 67.8% | $9.4M | +21.0% | $19.3M | $6.7M | $7.8M | $9.3M |
| Non-US | 32.2% | $4.5M | +24.4% | $7.1M | $2.7M | $3.6M | $3.5M |
Source: company filings via FMP. YoY compares the same fiscal period a year earlier.